JP2023503396A5 - - Google Patents
Info
- Publication number
- JP2023503396A5 JP2023503396A5 JP2022524618A JP2022524618A JP2023503396A5 JP 2023503396 A5 JP2023503396 A5 JP 2023503396A5 JP 2022524618 A JP2022524618 A JP 2022524618A JP 2022524618 A JP2022524618 A JP 2022524618A JP 2023503396 A5 JP2023503396 A5 JP 2023503396A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- pharmaceutical combination
- combination product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019120055 | 2019-11-21 | ||
| CNPCT/CN2019/120055 | 2019-11-21 | ||
| PCT/CN2020/130075 WO2021098774A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503396A JP2023503396A (ja) | 2023-01-30 |
| JP2023503396A5 true JP2023503396A5 (https=) | 2023-11-29 |
Family
ID=75981031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524618A Pending JP2023503396A (ja) | 2019-11-21 | 2020-11-19 | 抗ｐｄ１抗体又は抗ｐｄｌ１抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230212291A1 (https=) |
| EP (1) | EP4061850A4 (https=) |
| JP (1) | JP2023503396A (https=) |
| KR (1) | KR20220103708A (https=) |
| CN (1) | CN115151563A (https=) |
| AU (1) | AU2020386583A1 (https=) |
| BR (1) | BR112022009147A2 (https=) |
| CA (1) | CA3156931A1 (https=) |
| IL (1) | IL293119A (https=) |
| MX (1) | MX2022006147A (https=) |
| WO (1) | WO2021098774A1 (https=) |
| ZA (1) | ZA202204423B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024240247A1 (en) * | 2023-05-25 | 2024-11-28 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies |
| TW202540189A (zh) * | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN112552401B (zh) * | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| CN106604742B (zh) * | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| US20180222989A1 (en) * | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| JP2021501801A (ja) * | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
-
2020
- 2020-11-19 BR BR112022009147A patent/BR112022009147A2/pt unknown
- 2020-11-19 MX MX2022006147A patent/MX2022006147A/es unknown
- 2020-11-19 IL IL293119A patent/IL293119A/en unknown
- 2020-11-19 EP EP20890523.2A patent/EP4061850A4/en not_active Withdrawn
- 2020-11-19 CN CN202080080884.XA patent/CN115151563A/zh active Pending
- 2020-11-19 AU AU2020386583A patent/AU2020386583A1/en active Pending
- 2020-11-19 WO PCT/CN2020/130075 patent/WO2021098774A1/en not_active Ceased
- 2020-11-19 JP JP2022524618A patent/JP2023503396A/ja active Pending
- 2020-11-19 US US17/778,685 patent/US20230212291A1/en active Pending
- 2020-11-19 CA CA3156931A patent/CA3156931A1/en active Pending
- 2020-11-19 KR KR1020227014832A patent/KR20220103708A/ko active Pending
-
2022
- 2022-04-20 ZA ZA2022/04423A patent/ZA202204423B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503396A5 (https=) | ||
| HRP20250199T1 (hr) | Bispecifična anti-bcma x anti-cd3 antitijela i njihove upotrebe | |
| JP2024037894A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2021527431A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP2021531764A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2023543152A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2022533538A5 (https=) | ||
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| JP2023543826A5 (https=) | ||
| JP2023502323A5 (https=) | ||
| JP2024504331A5 (https=) | ||
| JP2022519631A5 (https=) | ||
| JP2023503399A5 (https=) | ||
| JP2024520638A5 (https=) |